T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04457596 |
|
Recruitment Status :
Recruiting
First Posted : July 7, 2020
Last Update Posted : April 9, 2024
|
Sponsor:
Alliance for Clinical Trials in Oncology
Collaborators:
National Cancer Institute (NCI)
Seagen Inc.
Information provided by (Responsible Party):
Alliance for Clinical Trials in Oncology
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | January 2028 |
| Estimated Study Completion Date : | May 2035 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):